$PPCB News

Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

Propanc Biopharma To File CTA In Australia For Phase 1b Study In 30–40 Advanced Cancer Patients; Plans Two Phase 2 Studies In Pancreatic And Ovarian Cancers With 60 Patients Each

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

Propanc Biopharma Engages Manufacturer For Its Lead Asset PRP Ahead Of The Upcoming Phase 1b, First-in-Human Study In 30-40 Advanced Cancer Patients Suffering From Solid Tumors

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

Propanc Biopharma Q3 EPS $(0.28) Up From $(12.50) YoY

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma Files Prospectus Related To Resale Of Up To 15M Shares Of Common Stock By Selling Stockholder

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Propanc Biopharma Launches Multi-Year Anti-Aging And Cancer Research Collaboration With Universities Of Jaén And Granada

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Propanc Biopharma Highlights PRP Proenzyme Therapy Aimed At $3B+ Pancreatic Cancer Market With Grim 13% Survival Rate

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Propanc Biopharma To Quantify PRP Cancer Treatment In Conjunction With FyoniBio

Propanc Biopharma To Quantify PRP Cancer Treatment In Conjunction With FyoniBio

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Propanc Biopharma Novel Therapeutic Approach To Treatment And Prevention Of Metastatic Cancer Shows Tumor Growth Inhibition In Pancreatic Models

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Propanc Biopharma Q2 EPS $(0.30) Up From $(32.23) YoY

Wondering what's happening in today's after-hours session?